STOCK TITAN

Glaukos Corporation (GKOS) Form 4 Filings

GKOS NYSE

Here are the Form 4 insider transactions from Glaukos Corporation (GKOS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow GKOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GKOS filings page.

Rhea-AI Summary

GLAUKOS Corp (GKOS) Chairman & CEO Thomas William Burns exercised options covering 180,000 common shares on November 18, 2026, at a $45.71 exercise price; the reported option balance afterward was zero. He also sold 180,000 shares that day in multiple trades, with reported transaction-level weighted-average prices ranging from $232.61 to $245.90 per share.

The exercises and sales were made under a Rule 10b5-1 trading plan adopted August 20, 2026, covering options expiring March 15, 2027. The report lists indirect holdings of 1,141,593 shares through the Burns Family Trust, 238,107 through the Burns Annuity Trust, 120,000 through the Burns Charitable Remainder Trust, and 100,000 shares each through the Thomas W. Burns and Janet M. Burns Irrevocable Trusts.

Rhea-AI Summary

Glaukos Corp. SVP and Chief Financial Officer Alex R. Thurman exercised options for 15,000 common shares at a $45.71 exercise price on November 18, 2026, then sold 15,000 shares at reported weighted-average prices from $232.65 to $246.12 per share in 13 transactions. The option exercise and sales were made under a Rule 10b5-1 trading plan adopted August 18, 2026; the options expire March 15, 2027. The reported option position following the exercise was zero.

Rhea-AI Summary

Glaukos withheld 3,907 shares from its Chairman & CEO, Thomas William Burns, on April 9, 2024, at $87.61 per share for tax obligations when previously granted restricted stock units vested and were delivered. The Form 4 reports 65,060 securities beneficially owned as of filing, including 48,673 unvested and undelivered restricted stock units.

Rhea-AI Summary

Glaukos Corp. (GKOS) President & COO Joseph E. Gilliam exercised options covering 861 shares on November 16, 2026, at exercise prices of $48.46, $55.18 and $69.30 per share, and sold 861 common shares at $250 per share. The option exercises and sale were made under a Rule 10b5-1 trading plan adopted August 13, 2026.

Rhea-AI Summary

Glaukos Corp (GKOS) President & COO Joseph E. Gilliam exercised options for 44,917 common shares on November 12, 2026. The five reported option lots were 2,475 shares at $69.30, 7,500 shares in each of two lots at $48.46, and 11,250 and 16,192 shares at $55.18 per share.

Gilliam also sold 44,917 shares in six transactions that day; reported weighted-average sale prices ranged from $243.41 to $248.42 per share. The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

Rhea-AI Summary

GLAUKOS Corp (GKOS) President & COO Joseph E. Gilliam had 986 common shares withheld by the issuer on April 9, 2024, for tax withholding obligations upon vesting and delivery of shares underlying restricted stock units granted March 18, 2021. The reported price was $87.61 per share. Beneficial ownership reported as of the Form 4 filing date was 71,602 shares, including 40,039 restricted stock units not yet vested or delivered.

Rhea-AI Summary

GLAUKOS Corp (GKOS) director Gilbert H. Kliman exercised options for 2,500 shares on November 4, 2026, at $25.77 per share, then sold 2,500 shares at $253 per share that day. The filing reports 10,000 options remaining after the exercise, expiring December 13, 2027. No Rule 10b5-1 plan is reported. A footnote notes 2,501 restricted stock units that had not vested or been delivered, plus vested units whose delivery Kliman deferred.

Rhea-AI Summary

GLAUKOS Corp director Aimee S. Weisner reported a gift transfer of 2,382 shares of Common Stock on October 30, 2026, from her direct ownership to the Saeman-Weisner Family Trust. After the transfer, she reported 15,801 shares held directly and 31,887 shares through that trust. She also reported 2,000 shares through the Weisner Saeman Family Irrevocable Trust.

Rhea-AI Summary

GLAUKOS Corp (GKOS) Chief Development Officer Tomas Navratil exercised options on October 30, 2026, acquiring 4,181 shares at $55 per share and 8,788 shares at $85.94 per share. On the same date, he sold 44,436 shares across four reported transactions at weighted-average prices of $237.54, $238.56, $239.64 and $240.52 per share. The corresponding trade-price ranges were $237.09–$238.07, $238.11–$239.11, $239.13–$240.03 and $240.17–$240.87. No Rule 10b5-1 plan is reported.

Rhea-AI Summary

GLAUKOS Corp (GKOS) chief development officer Tomas Navratil had 755 common shares withheld by the issuer on April 9, 2024, to satisfy tax withholding obligations upon vesting and delivery of shares underlying restricted stock units. The transactions comprised 495 shares at $87.61 per share tied to units granted March 18, 2021, and 260 shares at $93.23 per share tied to units granted March 24, 2022.

Rhea-AI Summary

GLAUKOS Corp Chief Development Officer Tomas Navratil reported three direct sales of common stock on October 5, 2026: 888 shares at a weighted-average $163.93 per share, 327 at $164.78, and 312 at $165.60. The sales were made under a Rule 10b5-1 trading plan adopted June 12, 2026.

Rhea-AI Summary

GLAUKOS Corp chief development officer Tomas Navratil reported selling 1,615 common shares on September 25, 2026, across four transactions: 167 shares at a weighted-average $151.70 per share, 136 at $152.71, 229 at $154.24 and 1,083 at $154.88. The sales were made under a Rule 10b5-1 trading plan adopted June 12, 2026; each reported price reflects multiple trades.

Rhea-AI Summary

GLAUKOS Corp (GKOS) reported that its Chief Development Officer, Tomas Navratil, sold a total of 1,457 shares of common stock on September 16, 2026 in a series of open‑market transactions under a Rule 10b5-1 trading plan adopted on June 12, 2026.

The weighted‑average sale prices for the trades ranged from about $163.20 to $172.00 per share, and the officer’s holdings include 38,817 restricted stock units that have not yet vested or been delivered.

Rhea-AI Summary

GLAUKOS Corp (GKOS) reported that chief development officer Tomas Navratil sold a total of 13,744 shares of common stock on August 28, 2026, in three open-market transactions. The sales covered 7,643 shares at a weighted average price of $180.25 (with individual trades between $179.69 and $180.69), 6,091 shares at a weighted average price of $181.19 (with trades between $180.71 and $181.61), and 10 shares at $182.50. The prices reported are weighted averages, and detailed trade breakdowns are available upon request. Following these transactions, Navratil’s equity holdings include 38,817 restricted stock units that have not yet vested or been delivered.

Rhea-AI Summary

GLAUKOS Corp (GKOS) director Gilbert H. Kliman exercised stock options for 2,500 shares of common stock on 2026-08-19 at an exercise price of $25.77 per share. The resulting 2,500 common shares were then sold the same day at $190.00 per share. After the exercise, Kliman continued to hold stock options for 12,500 shares, and his equity awards also include 2,501 restricted stock units that are unvested or deferred.

Rhea-AI Summary

GLAUKOS Corp president and COO Joseph E. Gilliam reported multiple option exercises and related stock sales for GKOS on 2026-08-11. He exercised options covering 60,000 shares of Common Stock and acquired an equal number of shares, then sold 60,000 Common shares in two open-market transactions at weighted average prices of $178.89 and $180.49 per share. He also continues to hold 41,983 restricted stock units and 225 stock units from the Employee Stock Purchase Plan, which remain unvested or undelivered.

Rhea-AI Summary

Glaukos Corp senior vice president and chief financial officer Alex R. Thurman reported an options exercise and same-day sale of common stock. On August 7, 2026, he exercised stock options for 20,000 shares of common stock at an exercise price of $33.81 per share and acquired those shares, then sold 20,000 shares of common stock at a weighted average price of $180.13 per share in a sale in open market or private transactions. The option exercises and sale were effected pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2025. Following these transactions, his reported holdings include 5,230 restricted stock units that have not yet vested or been delivered and 225 stock units purchased through the Employee Stock Purchase Plan.

Rhea-AI Summary

Glaukos Corp director Leana Wen sold 525 shares of common stock on July 31, 2026 at $167.63 per share in a sale described as an open-market or private transaction. After the sale, she reports holding 21,092 shares, including 2,501 restricted stock units that are unvested or with deferred delivery. The transaction was not reported as made under a Rule 10b5-1 trading plan.

Rhea-AI Summary

GLAUKOS Corp SVP & Chief Financial Officer Alex R. Thurman exercised options for 10,000 shares of common stock at an exercise price of $38.68 per share on July 16, 2026, then sold 10,000 shares at $160.00 per share. The option exercises and sales were effected under a Rule 10b5-1 trading plan adopted on December 15, 2025. Equity holdings also include 5,230 unvested restricted stock units and 225 shares acquired through the Employee Stock Purchase Plan.

Rhea-AI Summary

Glaukos Corp SVP & Chief Financial Officer Alex R. Thurman exercised stock options for 10,000 shares of Common Stock at $38.68 per share and, on the same date, sold 10,000 shares at $155.00 per share in an open-market transaction, all under a Rule 10b5-1 trading plan.

After these transactions, he holds 43,681 shares directly, including 5,230 restricted stock units that have not yet vested or been delivered, and 10,000 stock options with a $38.68 exercise price expiring on October 6, 2026, which vest over four years from the grant date.

Rhea-AI Summary

Glaukos Corp SVP & Chief Financial Officer Alex R. Thurman reported an exercise-and-sale transaction in company stock. On July 6, 2026, he exercised stock options for 10,000 shares of common stock at $38.68 per share and, on the same date, sold 10,000 shares of common stock in an open-market transaction at $150.00 per share. After these transactions, he directly holds 43,681 shares of Glaukos common stock, in addition to 5,230 restricted stock units that are unvested. Both the sale and the option exercise were carried out under a Rule 10b5-1 trading plan adopted on December 15, 2025, indicating they were pre-arranged rather than opportunistic market trades.

Rhea-AI Summary

Glaukos Corp chief development officer Tomas Navratil reported a small open-market sale of company stock. On July 1, he sold 716 shares of Glaukos common stock at an average price of $139.06 per share in an open-market transaction.

After the sale, Navratil directly holds 87,634 shares of Glaukos common stock, so the transaction represents a minor portion of his overall stake. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, indicating it was scheduled in advance. His holdings also include 38,817 restricted stock units that have not yet vested or been delivered.

Rhea-AI Summary

Glaukos Corp chairman and CEO Thomas William Burns reported updated holdings of the company’s common stock, mainly through several family and charitable trusts. The filing lists indirect positions including 100,000 shares through the Janet M. Burns Irrevocable Trust and 1,141,593 shares through the Burns Family Trust.

The only actual share movement was a tax-withholding disposition of 4,059 directly held shares at $142.57 per share to satisfy tax obligations upon vesting and delivery of restricted stock units granted on March 18, 2021. After this, he directly holds 68,967 shares, and his position also includes 56,382 restricted stock units that have not yet vested or been delivered.

Rhea-AI Summary

GLAUKOS Corp President & COO Joseph E. Gilliam reported a routine tax-related share disposition. On the vesting and delivery of previously granted restricted stock units, the company withheld 1,056 shares of common stock to cover his tax withholding obligations at $142.57 per share.

After this withholding, Gilliam directly holds 72,363 shares of common stock. This position includes 41,983 restricted stock units that have been granted but have not yet vested or been delivered, reflecting ongoing equity-based compensation rather than an open-market sale.

Rhea-AI Summary

GLAUKOS Corp Chief Development Officer Tomas Navratil reported a small share disposition related to tax withholding, not a market sale. On this Form 4, 483 shares of common stock were withheld by the company at $142.57 per share to satisfy tax obligations upon vesting of restricted stock units granted on March 18, 2021.

After this tax-withholding event, Navratil directly holds 88,350 shares of GLAUKOS common stock, which the filing notes include 38,817 restricted stock units that have not yet vested or been delivered. This filing reflects a routine compensation and tax event rather than an open-market trade.

Rhea-AI Summary

Glaukos Corp director Mark J. Foley reported a grant of 2,987 stock options for common stock, each with an exercise price of $106.52. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the May 28, 2026 grant date.

This Form 4/A corrects an earlier filing that mistakenly listed the exercise price as $53.57. After this grant, Foley holds 2,987 stock options from this award, which are scheduled to expire on May 28, 2036 if not exercised.

Rhea-AI Summary

Glaukos Corp director Leana Wen received a grant of stock options, and the amended Form 4 corrects their exercise price. On May 28, 2026 she was granted options for 2,987 shares of common stock at an exercise price of $106.52 per share, expiring on May 28, 2036. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the grant date. After this grant, she holds 2,987 stock options directly.

Rhea-AI Summary

GLAUKOS Corp director Marc Stapley reported a grant of stock options for 2,987 shares of Common Stock. These options carry an exercise price of $106.52 per share and were granted on May 28, 2026 under the issuer's Director Compensation Policy.

The options vest in full on the one-year anniversary of the grant date and expire on May 28, 2036. This Form 4/A also corrects a prior filing that had mistakenly reported the exercise price as $53.57, confirming the correct price as $106.52.

Rhea-AI Summary

Glaukos Corp director Aimee S. Weisner received a grant of 2,987 stock options as director compensation. The options have an exercise price of $106.52 per share, were granted on May 28, 2026, and vest in full on the one-year anniversary of the grant date. They are scheduled to expire on May 28, 2036. This amended Form 4 corrects an earlier filing that had reported the exercise price incorrectly, and reflects a routine equity award rather than an open-market stock purchase or sale.

Rhea-AI Summary

GLAUKOS Corp director Gilbert H. Kliman received a grant of 2,987 stock options, each with an exercise price of $106.52. The options relate to common stock and were awarded under the company’s Director Compensation Policy as part of his board compensation.

This Form 4/A is an amendment to a prior filing that had mistakenly reported the exercise price as $53.57. The options were granted on May 28, 2026, vest in full on the one-year anniversary of the grant date, and expire on May 28, 2036.

Rhea-AI Summary

GLAUKOS Corp director David F. Hoffmeister received a grant of 2,987 stock options, and the company corrected the reported exercise price. The amended Form 4 updates a prior filing that mistakenly listed the strike price as $53.57; the correct exercise price is $106.52. These options, granted under the issuer’s Director Compensation Policy, vest in full on the one-year anniversary of the May 28, 2026 grant date and are exercisable until May 28, 2036, giving him the right to buy an equal number of common shares at that price.

Rhea-AI Summary

GLAUKOS Corp director Denice Torres reported a stock option grant and corrected prior disclosure details. She received options for 2,987 shares of common stock at an exercise price of $106.52 per share, granted under the issuer's Director Compensation Policy. The options vest in full on the one-year anniversary of the May 28, 2026 grant date and expire on May 28, 2036. This Form 4/A also amends a prior Form 4 that mistakenly reported the exercise price as $53.57, clarifying that the correct exercise price is $106.52.

Rhea-AI Summary

Glaukos Corp’s chief development officer Tomas Navratil sold 1,537 shares of common stock in an open-market trade. The sale was executed at an average price of $130.68 per share under a Rule 10b5-1 trading plan adopted on March 12, 2026.

After this transaction, he directly holds 88,833 shares of Glaukos common stock, which includes 39,791 restricted stock units that have not yet vested or been delivered.

Rhea-AI Summary

GLAUKOS Corp director Leana Wen reported receiving equity compensation on May 28, 2026. She was granted 1,878 restricted stock units under the company’s Director Compensation Policy; these units vest in full one year after the grant and will be settled in an equal number of common shares.

She also received a stock option for 2,987 shares of common stock at an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. After these awards, Wen directly holds 21,617 shares of common stock, which the filing notes include previously granted restricted stock units that are unvested or deferred.

Rhea-AI Summary

GLAUKOS Corp director Aimee S. Weisner received new equity compensation awards. On May 28, 2026, she was granted 1,878 restricted stock units under the company’s Director Compensation Policy. These units vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of common shares.

She was also granted 2,987 stock options with an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. Following these awards, she holds 20,684 common shares directly, in addition to indirect holdings of 2,000 shares through the Weisner Saeman Family Irrevocable Trust and 29,505 shares through the Saeman-Weisner Family Trust. These are compensation-related grants rather than open-market purchases or sales.

Rhea-AI Summary

GLAUKOS Corp director Denice Torres reported equity awards as part of standard board compensation. She received 1,878 restricted stock units that will vest in full on the one-year anniversary of the grant date and convert into the same number of common shares. She was also granted stock options for 2,987 shares of common stock with an exercise price of $53.57 per share, vesting in full after one year and expiring in 2036. Following these grants, she directly holds 24,212 shares of common stock, which include 4,609 restricted stock units that have not yet vested or been delivered.

Rhea-AI Summary

GLAUKOS Corp director Mark J. Foley received equity compensation consisting of new restricted stock units and stock options. He was granted 1,878 restricted stock units under the company’s Director Compensation Policy, which will vest in full on the one-year anniversary of the grant date and then convert into the same number of common shares.

Foley was also granted stock options covering 2,987 shares of common stock with an exercise price of $53.57 per share, also vesting in full one year after the grant date and expiring in 2036. After these awards, he directly holds 60,267 shares of common stock, including 5,154 restricted stock units that have not yet vested or been delivered, highlighting this filing as a routine, compensation-related acquisition rather than an open-market purchase or sale.

Rhea-AI Summary

GLAUKOS Corp director David F. Hoffmeister reported equity compensation awards. He received 1,878 restricted stock units under the company’s Director Compensation Policy, which vest in full on the one-year anniversary of the May 28 grant and are payable in the same number of common shares.

He also received stock options for 2,987 shares of common stock at an exercise price of $53.57 per share, vesting in full after one year and expiring on May 28, 2036. Following these awards, he holds 49,549 shares directly, including 4,739 unvested or deferred restricted stock units, and 38,176 shares indirectly through Sentinel Point Partners, Inc.

Rhea-AI Summary

GLAUKOS Corp director Gilbert H. Kliman received new equity awards as part of the company’s director compensation program. He was granted 1,878 shares of common stock in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and will be settled in an equal number of shares.

He also received a stock option for 2,987 shares of common stock with an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. After these awards, Kliman directly holds 37,406 shares of common stock. Footnote disclosure states this total includes 4,609 restricted stock units that are either unvested or vested but with delivery deferred.

Rhea-AI Summary

GLAUKOS Corp director Marc Stapley reported compensation-related equity grants. He received 1,878 restricted stock units under the company’s Director Compensation Policy, which vest in full on the one-year anniversary of the May 28, 2026 grant and will be settled in the same number of common shares. He was also granted stock options covering 2,987 shares of common stock at an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. Following these awards, Stapley directly holds 39,327 shares of common stock, which include 4,713 restricted stock units that are unvested or deferred for later delivery.

Rhea-AI Summary

GLAUKOS Corp director David F. Hoffmeister exercised stock options to acquire 15,000 shares of Common Stock at $24.69 per share. The exercised options were granted on June 2, 2016 and were fully vested by the first anniversary of the grant date, and now show zero remaining. After the transaction, he holds 47,671 shares of Common Stock directly, which include 2,861 restricted stock units that are unvested or deferred, and 38,176 shares indirectly through Sentinel Point Partners, Inc.

Rhea-AI Summary

GLAUKOS Corp director Gilbert H. Kliman exercised stock options and sold shares in the company. He exercised options for 5,000 shares of common stock at $24.69 per share, then sold 5,000 shares in the open market at an average price of $140.76 per share.

After these transactions, he directly owns 35,528 shares of common stock, which includes 2,731 restricted stock units that have not yet vested or been delivered, as well as vested units with deferred delivery. The option exercised was granted on June 2, 2016 and fully vested one year later, with no remaining balance after this exercise.

Rhea-AI Summary

GLAUKOS Corp director Gilbert H. Kliman reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 5,000 shares of Common Stock at $24.69 per share and on the same day sold 5,000 Common Stock shares in an open-market sale at $135.00 per share.

After these transactions, he directly holds 35,528 Common Stock shares, which include 2,731 restricted stock units that are unvested or deferred. The option exercised was originally granted on June 2, 2016 and had fully vested by the first anniversary of the grant date.

Rhea-AI Summary

GLAUKOS Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported an exercise-and-sell transaction in company stock. On April 30, 2026, he exercised stock options to acquire 10,000 shares of common stock at $38.68 per share, then sold 10,000 shares in open-market transactions at $140.00 per share.

Following these transactions, he directly owns 43,681 shares of common stock, which includes 5,230 restricted stock units that have not yet vested or been delivered. Both the sales and the option exercises were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating the activity was scheduled in advance.

Rhea-AI Summary

GLAUKOS Corp executive Joseph E. Gilliam, the company’s President and COO, reported an open-market sale of 19,573 shares of common stock at a price of $143.54 per share.

After this transaction, he directly held 73,419 shares, which includes 43,925 restricted stock units that have not yet vested or been delivered.

Rhea-AI Summary

GLAUKOS Corp director Leana Wen reported an open-market sale of 1,700 shares of common stock at $143.35 per share. After this transaction, she directly holds 19,739 shares, which the filing states includes 2,731 restricted stock units that are unvested or with deferred delivery.

Rhea-AI Summary

Glaukos Corp’s chief development officer, Tomas Navratil, sold 2,093 shares of common stock in open‑market trades. The sales on April 10, 2026 were executed at prices ranging from about $116.72 to $120.23 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 12, 2026.

After these transactions, Navratil directly holds 90,370 shares of Glaukos common stock, which includes 39,791 restricted stock units that have not yet vested or been delivered. The filing notes that several trades were executed in multiple lots, with the reported prices reflecting weighted averages.

Rhea-AI Summary

Glaukos Corp’s Chief Development Officer Tomas Navratil reported a routine tax-withholding disposition of 2,977 shares of common stock. The issuer withheld 1,146 shares and 1,831 shares at $109.60 per share to cover tax obligations upon vesting and delivery of restricted stock units granted in 2022 and 2024.

After these withholdings, Navratil directly owns 92,463 shares of common stock. His position also reflects 43,483 restricted stock units from the March 24, 2022 grant and 39,791 restricted stock units from the March 14, 2024 grant that have not yet vested or been delivered.

Rhea-AI Summary

GLAUKOS Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported a routine tax-related share disposition. On the vesting and delivery of previously granted restricted stock units, the company withheld 1,589 shares of common stock to satisfy his tax withholding obligations.

After this non-market transaction, Thurman directly holds 43,681 shares of common stock. Footnotes also state he has 5,230 restricted stock units that have not yet vested or been delivered, indicating additional potential future equity awards.

Rhea-AI Summary

GLAUKOS Corp president and COO Joseph E. Gilliam reported a routine tax-withholding share disposition tied to equity compensation. On the vesting and delivery of previously granted restricted stock units, 3,169 shares of common stock were withheld by the company at $109.60 per share to cover his tax obligations.

After this non-market transaction, he directly holds 92,992 shares of GLAUKOS common stock, including 43,925 restricted stock units that have not yet vested or been delivered. The filing does not reflect an open-market purchase or sale, but rather the automated tax treatment of stock-based compensation.